A nomogram to predict "pure" vs. "mixed" uric acid urinary stones.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
31 Oct 2024
Historique:
received: 10 08 2024
accepted: 22 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 31 10 2024
Statut: epublish

Résumé

Uric acid stones (UAS) can be treated non-invasively by oral chemolysis. However, it is crucial to identify individuals who are most likely to benefit from this approach, specifically, patients with pure UAS. The aim of this study was to develop a nomogram that can differentiate between pure and mixed UAS. A retrospective analysis of demographic, clinical and stone composition data of patients with a predominant UAS composition (≥ 50%) treated between 2014 and 2022. A total of 135 patients were included in the analysis, 37.8% had mixed UAS (50-90% UA) and 62.2% had pure UAS (≥ 95% UA). The mean stone density and the percentage of radiopaque stones in the pure UAS group were significantly lower than those in the mixed UAS group (450 Hounsfield Units [HU] vs. 600 HU, and 24% vs. 58%, respectively). A stepwise multivariate logistic regression revealed that lower stone density, bigger size, decreased stone opacity and older age are predictive variables for pure UAS. Accordingly, a nomogram was generated with a receiver operating characteristic (ROC) curve that showed an area under the curve (AUC) of 0.78. A patient with a total score of 156 has a probability of > 95% for pure UAS. Imaging and demographic data can be used to identify patients with pure UAS. The nomogram may be useful for counseling patients regarding oral chemolysis. Future validation of the nomogram with a different data set is required to assess its efficacy.

Identifiants

pubmed: 39480595
doi: 10.1007/s00345-024-05340-3
pii: 10.1007/s00345-024-05340-3
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

610

Informations de copyright

© 2024. The Author(s).

Références

Stamatelou K, Goldfarb DS (2023) Epidemiology of kidney stones. Healthc (Basel) 11
Xu LHR, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K (2017) Temporal changes in kidney stone composition and in risk factors predisposing to stone formation. J Urol 197:1465–1471
doi: 10.1016/j.juro.2017.01.057 pubmed: 28111301 pmcid: 5433898
Kravdal G, Helgø D, Moe MK (2019) Kidney stone compositions and frequencies in a Norwegian population. Scand J Urol 53:139–144
doi: 10.1080/21681805.2019.1606031 pubmed: 31070078
Negri AL, Spivacow R, Del Valle E, Pinduli I, Marino A, Fradinger E et al (2007) Clinical and biochemical profile of patients with pure uric acid nephrolithiasis compared with pure calcium oxalate stone formers. Urol Res 35:247–251
doi: 10.1007/s00240-007-0109-1 pubmed: 17786420
Abate N, Chandalia M, Cabo-Chan AV Jr., Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65:386–392
doi: 10.1111/j.1523-1755.2004.00386.x pubmed: 14717908
Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH (2001) Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int 60:757–761
doi: 10.1046/j.1523-1755.2001.060002757.x pubmed: 11473659
Spatola L, Ferraro PM, Gambaro G, Badalamenti S, Dauriz M (2018) Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism 83:225–233
doi: 10.1016/j.metabol.2018.02.008 pubmed: 29510180
Sakhaee K (2014) Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol 27:241–245
doi: 10.1007/s40620-013-0034-z pubmed: 24497296 pmcid: 4696481
Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K (2006) Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 17:1422–1428
doi: 10.1681/ASN.2005121246 pubmed: 16597681
Friedlander JI, Moreira DM, Hartman C, Elsamra SE, Smith AD, Okeke Z (2014) Comparison of the metabolic profile of mixed calcium oxalate/uric acid stone formers to that of pure calcium oxalate and pure uric acid stone formers. Urology 84:289–294
doi: 10.1016/j.urology.2014.04.019 pubmed: 24929942
Usman KD, Golan S, Abdin T, Livne PM, Pode D, Duvdevani M et al (2013) Urinary stone composition in Israel: current status and variation with age and sex–a bicenter study. J Endourol 27:1539–1542
doi: 10.1089/end.2013.0236 pubmed: 24266775
Nevo A, Levi O, Sidi A, Tsivian A, Baniel J, Margel D et al (2020) Patients treated for uric acid stones reoccur more often and within a shorter interval compared to patients treated for calcium stones. Can Urol Assoc J 14:E555–e59
pubmed: 32520701 pmcid: 7673824
Elsawy AA, Elshal AM, El-Nahas AR, Elbaset MA, Farag H, Shokeir AA (2019) Can we predict the outcome of oral dissolution therapy for Radiolucent Renal Calculi? A prospective study. J Urol 201:350–357
doi: 10.1016/j.juro.2018.09.027 pubmed: 30218763
Tsaturyan A, Bokova E, Bosshard P, Bonny O, Fuster DG, Roth B (2020) Oral chemolysis is an effective, non-invasive therapy for urinary stones suspected of uric acid content. Urolithiasis 48:501–507
doi: 10.1007/s00240-020-01204-8 pubmed: 32770255
Salem SM, Sultan MF, Badawy A (2019) Oral dissolution therapy for renal radiolucent stones, outcome, and factors affecting response: a prospective study. Urol Ann 11:369–373
doi: 10.4103/UA.UA_20_19 pubmed: 31649455
Sinha M, Prabhu K, Venkatesh P, Krishnamoorthy V (2013) Results of urinary dissolution therapy for radiolucent calculi. Int Braz J Urol 39:103–107
doi: 10.1590/S1677-5538.IBJU.2013.01.13 pubmed: 23489502
Trinchieri A, Esposito N, Castelnuovo C (2009) Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate. Arch Ital Urol Androl 81:188–191
pubmed: 19911683
Gridley CM, Sourial MW, Lehman A, Knudsen BE (2019) Medical dissolution therapy for the treatment of uric acid nephrolithiasis. World J Urol 37:2509–2515
doi: 10.1007/s00345-019-02688-9 pubmed: 30810833
Torricelli FC, Brown R, Berto FC, Tarplin S, Srougi M, Mazzucchi E et al (2015) Nomogram to predict uric acid kidney stones based on patient’s age, BMI and 24-hour urine profiles: a multicentre validation. Can Urol Assoc J 9:E178–E182
doi: 10.5489/cuaj.2682 pubmed: 26085876
Wiessmeyer JR, Ozimek T, Struck JP, Hupe MC, Willig J, Merseburger AS et al (2022) Comprehensive Nomogram for Prediction of the uric acid composition of Ureteral stones as a part of tailored Stone Therapy. Eur Urol Focus 8:291–296
doi: 10.1016/j.euf.2021.02.001 pubmed: 33589393
Primak AN, Fletcher JG, Vrtiska TJ, Dzyubak OP, Lieske JC, Jackson ME et al (2007) Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. Acad Radiol 14:1441–1447
doi: 10.1016/j.acra.2007.09.016 pubmed: 18035274 pmcid: 2743375
Marchini GS, Remer EM, Gebreselassie S, Liu X, Pynadath C, Snyder G et al (2013) Stone characteristics on noncontrast computed tomography: establishing definitive patterns to discriminate calcium and uric acid compositions. Urology 82:539–546
doi: 10.1016/j.urology.2013.03.092 pubmed: 23987148
Zarse CA, McAteer JA, Tann M, Sommer AJ, Kim SC, Paterson RF et al (2004) Helical computed tomography accurately reports urinary stone composition using attenuation values: in vitro verification using high-resolution micro-computed tomography calibrated to fourier transform infrared microspectroscopy. Urology 63:828–833
doi: 10.1016/j.urology.2003.11.038 pubmed: 15134957
Kambadakone AR, Eisner BH, Catalano OA, Sahani DV (2010) New and evolving concepts in the imaging and management of urolithiasis: urologists’ perspective. Radiographics 30:603–623
doi: 10.1148/rg.303095146 pubmed: 20462984
Pareek G, Armenakas NA, Fracchia JA (2003) Hounsfield units on computerized tomography predict stone-free rates after extracorporeal shock wave lithotripsy. J Urol 169:1679–1681
doi: 10.1097/01.ju.0000055608.92069.3a pubmed: 12686807
Kulkarni NM, Eisner BH, Pinho DF, Joshi MC, Kambadakone AR, Sahani DV (2013) Determination of renal stone composition in phantom and patients using single-source dual-energy computed tomography. J Comput Assist Tomogr 37:37–45
doi: 10.1097/RCT.0b013e3182720f66 pubmed: 23321831
Torricelli FC, De S, Liu X, Calle J, Gebreselassie S, Monga M (2014) Can 24-hour urine stone risk profiles predict urinary stone composition? J Endourol 28:735–738
doi: 10.1089/end.2013.0769 pubmed: 24460026
Spettel S, Shah P, Sekhar K, Herr A, White MD (2013) Using Hounsfield unit measurement and urine parameters to predict uric acid stones. Urology 82:22–26
doi: 10.1016/j.urology.2013.01.015 pubmed: 23688376
Saw KC, McAteer JA, Monga AG, Chua GT, Lingeman JE, Williams JC Jr. (2000) Helical CT of urinary calculi: effect of stone composition, stone size, and scan collimation. AJR Am J Roentgenol 175:329–332
doi: 10.2214/ajr.175.2.1750329 pubmed: 10915668
Fernandez A, Fuller A, Al-Bareeq R, Nott L, Razvi H (2013) A comparison of the metabolic profiles of diabetic and non-diabetic uric acid stone formers. Can Urol Assoc J 7:E190–E192
doi: 10.5489/cuaj.820 pubmed: 22398202 pmcid: 3650786
Reichard C, Gill BC, Sarkissian C, De S, Monga M (2015) 100% uric acid stone formers: what makes them different? Urology 85:296–298
doi: 10.1016/j.urology.2014.10.029 pubmed: 25623669

Auteurs

Liran Zieber (L)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

Gherman Creiderman (G)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

Muhammad Krenawi (M)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

Daniel Rothenstein (D)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

Dmitry Enikeev (D)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
Urology Department, Medical University of Vienna, Vienna, Austria.

Yaron Ehrlich (Y)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

David Lifshitz (D)

Institute of Urology, Rabin Medical Center, Petah Tikva, Israel. davidlif@clalit.org.il.
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel. davidlif@clalit.org.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH